Xuanzhu Biology: has submitted the application for the full circulation of H shares to the China Securities Regulatory Commission.

Xuanzhu Bios announcement, the company has submitted a filing application to the China Securities Regulatory Commission regarding the proposal to implement full circulation of H shares, converting a total of 357 million shares of unlisted shares into H shares on a one-to-one basis. Upon completion of all filing requirements, obtaining all relevant approvals, and complying with all applicable laws, regulations, and rules, the 357 million unlisted shares will be converted into 357 million H shares and will be listed and traded on the Hong Kong Stock Exchange.